Tags

Type your tag names separated by a space and hit enter

No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: the Alpha Omega Trial.
Eur J Prev Cardiol 2015; 22(5):648-55EJ

Abstract

BACKGROUND

heart failure is a major risk factor for cardiovascular mortality, for which n-3 fatty acids may have beneficial effects. We examined the effect of marine eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and plant-derived alpha-linolenic acid (ALA) on N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP), a biomarker of heart failure.

METHODS

we randomly assigned 4837 post-myocardial infarction patients, aged 60-80 years (82% men), to margarines supplemented with a targeted additional intake of 400 mg/day EPA and DHA, 2 g/day ALA, EPA-DHA plus ALA, or placebo for 40 months. In a random selection of 639 patients, NT-proBNP was determined both at baseline and at the end of follow-up. NT-proBNP was loge-transformed and analysed by type of treatment using analysis of covariance adjusting for baseline NT-proNBP.

RESULTS

patients consumed on average 19.8 g margarine/day, providing an additional amount of 238 mg/day EPA with 158 mg/day DHA, 1.98 g/day ALA, or both, in the active-treatment groups. In the placebo group, the geometric mean level NT-proBNP increased from 245 ng/l (95%-confidence interval [CI]: 207-290) to 294 ng/l (95%-CI: 244-352) after 40 months (p = 0.001). NT-proBNP levels were not affected by ALA (+8% versus placebo; 95%-CI: -8% to +25%; p = 0.34), EPA-DHA (+2% versus placebo; 95%-CI: -14% to +18%; p = 0.78), nor EPA-DHA plus ALA (+9% versus placebo; 95%-CI: -8% to +25%; p = 0.31) treatment.

CONCLUSIONS

supplementation with modest amounts of EPA-DHA, with or without ALA, did not have a significant effect on NT-proBNP levels in patients with a history of myocardial infarction.

Authors+Show Affiliations

Department of Internal Medicine and Nephrology, Jeroen Bosch Hospital, Den Bosch, the Netherlands ellen.hoogeveen@planet.nl.Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands.Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands.Department of Clinical Chemistry, Jeroen Bosch Hospital, Den Bosch, the Netherlands.Department of Clinical Chemistry, Jeroen Bosch Hospital, Den Bosch, the Netherlands.Department of Clinical Chemistry, Jeroen Bosch Hospital, Den Bosch, the Netherlands.Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

24879357

Citation

Hoogeveen, Ellen K., et al. "No Effect of N-3 Fatty Acids Supplementation On NT-proBNP After Myocardial Infarction: the Alpha Omega Trial." European Journal of Preventive Cardiology, vol. 22, no. 5, 2015, pp. 648-55.
Hoogeveen EK, Geleijnse JM, Kromhout D, et al. No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: the Alpha Omega Trial. Eur J Prev Cardiol. 2015;22(5):648-55.
Hoogeveen, E. K., Geleijnse, J. M., Kromhout, D., van't Sant, P., Gemen, E. F., Kusters, R., & Giltay, E. J. (2015). No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology, 22(5), pp. 648-55. doi:10.1177/2047487314536694.
Hoogeveen EK, et al. No Effect of N-3 Fatty Acids Supplementation On NT-proBNP After Myocardial Infarction: the Alpha Omega Trial. Eur J Prev Cardiol. 2015;22(5):648-55. PubMed PMID: 24879357.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: the Alpha Omega Trial. AU - Hoogeveen,Ellen K, AU - Geleijnse,Johanna M, AU - Kromhout,Daan, AU - van't Sant,Peter, AU - Gemen,Eugenie F, AU - Kusters,Ron, AU - Giltay,Erik J, Y1 - 2014/05/30/ PY - 2014/01/10/received PY - 2014/05/01/accepted PY - 2014/6/1/entrez PY - 2014/6/1/pubmed PY - 2016/2/18/medline KW - NT-proBNP KW - alpha-linolenic acid KW - docosahexaenoic acid KW - eicosapentaenoic acid KW - n-3 Polyunsaturated fatty acids KW - randomized double-blind placebo-controlled trial SP - 648 EP - 55 JF - European journal of preventive cardiology JO - Eur J Prev Cardiol VL - 22 IS - 5 N2 - BACKGROUND: heart failure is a major risk factor for cardiovascular mortality, for which n-3 fatty acids may have beneficial effects. We examined the effect of marine eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and plant-derived alpha-linolenic acid (ALA) on N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP), a biomarker of heart failure. METHODS: we randomly assigned 4837 post-myocardial infarction patients, aged 60-80 years (82% men), to margarines supplemented with a targeted additional intake of 400 mg/day EPA and DHA, 2 g/day ALA, EPA-DHA plus ALA, or placebo for 40 months. In a random selection of 639 patients, NT-proBNP was determined both at baseline and at the end of follow-up. NT-proBNP was loge-transformed and analysed by type of treatment using analysis of covariance adjusting for baseline NT-proNBP. RESULTS: patients consumed on average 19.8 g margarine/day, providing an additional amount of 238 mg/day EPA with 158 mg/day DHA, 1.98 g/day ALA, or both, in the active-treatment groups. In the placebo group, the geometric mean level NT-proBNP increased from 245 ng/l (95%-confidence interval [CI]: 207-290) to 294 ng/l (95%-CI: 244-352) after 40 months (p = 0.001). NT-proBNP levels were not affected by ALA (+8% versus placebo; 95%-CI: -8% to +25%; p = 0.34), EPA-DHA (+2% versus placebo; 95%-CI: -14% to +18%; p = 0.78), nor EPA-DHA plus ALA (+9% versus placebo; 95%-CI: -8% to +25%; p = 0.31) treatment. CONCLUSIONS: supplementation with modest amounts of EPA-DHA, with or without ALA, did not have a significant effect on NT-proBNP levels in patients with a history of myocardial infarction. SN - 2047-4881 UR - https://www.unboundmedicine.com/medline/citation/24879357/No_effect_of_n_3_fatty_acids_supplementation_on_NT_proBNP_after_myocardial_infarction:_the_Alpha_Omega_Trial_ L2 - http://journals.sagepub.com/doi/full/10.1177/2047487314536694?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -